PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.71%
Similar G&A growth to CRVO's 37.03%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
-38.54%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
25.41%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
25.41%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
-10.64%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
353.66%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
100.00%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-610.74%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
610.74%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
609.26%
EPS growth while CRVO declines. John Neff would investigate advantages.
609.26%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.